A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

NCT02867566 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

420

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse, Large B-Cell, Lymphoma

Interventions

DRUG: IBI301 plus CHOP
DRUG: Rituximab plus CHOP

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.